<DOC>
	<DOCNO>NCT00986336</DOCNO>
	<brief_summary>The purpose study assess potential pharmacokinetic ( absorption , distribution excretion drug body ) interaction , safety , topiramate risperidone administer combination patient history either bipolar spectrum schizoaffective ( bipolar type ) disorder define DSM-IV criterion .</brief_summary>
	<brief_title>A Pharmacokinetic Study Risperidone Topiramate Administered Alone Combination Patients With Bipolar Disorder Schizoaffective Disorders</brief_title>
	<detailed_description>This open-label ( investigator patient know identity study drug ) , nonrandomized pharmacokinetic ( PK ) study evaluate interaction topiramate risperidone patient bipolar disorder . The study enrol sufficient number patient obtain 24 complete patient . Patients men woman age 18 55 year , inclusive , diagnosis Bipolar Spectrum Schizoaffective Disorder , midst acute episode , experience acute manic , major depressive , schizoaffective episode minimum 30 day prior screen ( enrollment monitor ensure least one-third study sample sex . ) The study consist screen phase 3 treatment period . In Period I , patient stabilize clinically appropriate dose risperidone within range 1 6 mg/day , administer divided dos every 12 hour 2- 3-week period ( longer clinically necessary ) . Upon risperidone stabilization , serial blood urine sample obtain 12 hour postdose estimation risperidone metabolite 9-OH-risperidone ( metabolite form metabolism drug ) concentration Period I . In Period II , last 6 week longer clinically necessary , topiramate gradually escalated 3 steady-state target dos , risperidone therapy continue unchanged . There 3 PK sample period ( day multiple blood urine sample take estimate amount topiramate /or risperidone metabolite 9-OH-risperidone blood urine ) patient achieve steady state 100 mg/day topiramate ( consistent amount drug blood dose ) ; when/if patient achieve steady state 250 mg/day topiramate maximum tolerate dose ( MTD ) ; when/if patient achieve steady state 400 mg/day topiramate MTD . During PK sample visit Period II , serial blood urine sample obtain 12 hour postdose estimation risperidone , 9-OH risperidone , topiramate concentration . In Period III , risperidone gradually taper 400-mg/day dose ( MTD ) topiramate maintain . There 2 PK sample visit : patient attain steady state dose 50 % maximal risperidone dose reach Period I ; risperidone discontinue 7 day patient maintain topiramate 400 mg/day respective MTD . During PK sample visit Period III , serial blood urine sample obtain 12 hour postdose estimation risperidone , 9-OH risperidone , topiramate concentration . Period I ( risperidone stabilization ) : risperidone 1-6 mg/day 2 3 week . Period II ( topiramate dose escalation ) : topiramate administer approximately 6 week titrate 3 potential target dos ( 100 mg/day , 250 mg/day 400 mg/day ) , risperidone continue unchanged . Period III ( risperidone dose reduction ) : risperidone dose taper zero 4-week period topiramate maintain target dose 400 mg/day ( MTD ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients meet DSMIV criterion either Bipolar I Disorder , Bipolar II Disorder , Cyclothymic Disorder , Bipolar Disorder NOS , Schizoaffective Disorder ( bipolar type ) Patients midst acute manic , major depressive , schizoaffective episode experience acute episode within month prior screen Women postmenopausal least 1 year , surgically incapable childbearing , practice acceptable method birth control ( hormonal contraception , intrauterine device , barrier spermicide acceptable ) pregnant baseline . Patients history acquire hereditary neurologic disease , e.g. , epilepsy significant brain trauma Patients use prescription medication , include psychotropic medication , within 14 day prior first day Period I exception hormonal contraceptive ( woman ) , risperidone , medication approve sponsor Patients depot medication ( include limit haloperidol decanoate ) Patients take acetazolamide , zonisamide , triamterene , dichlorphenamide , chronic antacid , calcium supplement , medication associate nephrolithiasis month prior begin TPM titration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>topiramate</keyword>
	<keyword>risperidone , bipolar disorder</keyword>
</DOC>